Zydus Lifesciences arm gets marketing nod for Nulibry from UK MHRA for MoCD Type A

NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy that was approved by the U.S. Food and Drug Administration (FDA) in 2021 to reduce the risk of mortality in patients with MoCD Type A.

"Following this decision by the UK MHRA, NULIBRY is the first and only approved therapy in GB for MoCD Type A," the Company stated.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd., said, “We are happy that with the UK MHRA approval of NULIBRY which will enable access to this critical drug and treat an ultra-rare disorder. Healthcare providers in Great Britain can now bridge the unmet needs of patients with this innovative treatment.”

Matt Heck, President & Chief Executive Officer of Sentynl said, “This approval advances our mission to make a positive impact in the lives of patients suffering from rare diseases, especially one as devastating as MoCD Type A.”

NULIBRY’s MHRA approval was supported by data from three clinical trials that demonstrated the safety and efficacy of NULIBRY for the treatment of patients with MoCD Type A compared to data from a natural history study. These studies showed that NULIBRYtreated patients had a 5.5 times lower risk of death than that of the untreated patients. Moreover, the survival probability at 3 years of age was 85.5% for NULIBRY-treated patients and 55.1% for untreated control patients.

Read also: Zydus Lifesciences gets WHO INN approval for 'Usnoflast' as recommended name for ZYIL1